Search Results

Deals

Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology

Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.

March 2, 2023

·

5 min read

Drug Development

Dynacure Axes Investigational Study of CNM Treatment

Dynacure has ended its Unite-CNM Phase I/II trial on DYN101, an investigational therapy for the treatment of myotubular and centronuclear myopathies.

July 8, 2022

·

2 min read

·

Vanessa Doctor, RN

Business

Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced that Dynacure and Nippon Shinyaku Co., Ltd. have entered a long-term strategic development and commercialization agreement.

November 10, 2021

·

6 min read

Pharm Country

Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference

Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies, a group of rare, debilitating and life-threatening genetic diseases, announced that Stephane van Rooijen, M.D., president & chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.

January 3, 2022

·

1 min read

Pharm Country

Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies

Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101.

January 6, 2022

·

3 min read

Pharm Country

Dynacure to Present Preclinical Data on Disease Progression Modelling and ASO-Mediated Dynamin 2 Knockdown at World Muscle Society (WMS) Meeting

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, will present three posters at the 26th Annual Congress of the World Muscle Society (WMS).

September 16, 2021

·

5 min read

Policy

Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies

Dynacure announced that the US Food and Drug Administration has accepted its Investigational New Drug application for DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein, for the treatment of Myotubular and Centronuclear Myopathies.

June 9, 2021

·

4 min read

Business

Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the appointment of Jean M. Franchi to its Board of Directors.

January 21, 2021

·

3 min read

Pharm Country

Dynacure Announces Presentations at Upcoming Investor Conferences

Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company is presenting at several virtual investor conferences during August 2020.

July 29, 2020

·

1 min read

Pharm Country

Dynacure Announces New Program, DYN201, for Hereditary Spastic Paraplegia (HSP), a Rare Neurodegenerative Disease

Dynacure acquires intellectual property from Paris Brain Institute to support DYN201 development

October 13, 2020

·

3 min read